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Background: The Assessment of SpondyloArthritis international Society Health Index (ASAS HI), is a
unidimensional questionnaire, that includes 17 items, measuring functioning and health in patients with
spondyloarthritis (SpA) (1). At the beginning of this project, only an English version of the instrument
existed.
Objectives: The aim of this study was to conduct the cross-cultural adaptation of the ASAS-HI into
European Portuguese language and investigate its reliability and validity in a sample of Portuguese
patients with SpA.
Methods: The ASAS-HI has a range from 0 (best health state) to 17 (worst health state). The
questionnaire was first translated and then back translated following published guidelines. Patients
fulfilling ASAS classification criteria for either axial (axSpA) or peripheral SpA (pSpA) were included.
Reliability was assessed through internal consistency coefficient, and internal consistency was assessed
using Cronbach's alpha. Construct validity was assessed through Spearman's correlation analyses
between the ASAS-HI and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath
Ankylosing Spondylitis Functional Index (BASFI), Ankylosing Spondylitis Disease Activity Score-CRP
(ASDAS-CRP), and the Short Form (36) Health Survey (SF-36) (physical) SF-36 (physical) for convergent
validity and between the ASAS-HI and the HAD-S Anxiety/Depression, and SF-36 (mental) for divergent
validity. Discriminative validity was tested comparing the ASAS-HI across ASDAS-CRP disease activity
states using the Kruskal–Wallis test.
Results: In total, 86 patients were included: 65% male, mean (SD) age 47.1 (12.9) years, symptom
duration 11.4 (11.0) years, BASDAI 3.1 (2.1), BASFI 2.2 (2.6), ASDAS-CRP 2.2 (0.8). The diagnosis of
axSpA was established in 58 patients (AS =45, nr-axSpA =13) and of pSpA in 28 patients. The forward
backward translation was successful and qualitative interviews raised no further comments of the
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patients. The total mean score of the ASAS-HI was 4.6 (3.8). The ASAS- HI showed an excellent test-
retest reliability (n=72) (ICC=0.93: 95% CI=0.89;0.96, p<0.001) and a good internal consistency
(Cronbachs-α of 0.87). According to the predefined hypothesis, the ASAS-HI correlated strongly with the
BASDAI (0.76, p<0.001), SF-36 (physical) (-0.75, p<0.001), moderately well with the HAD-S Anxiety (0.41,
p<0.001), and SF-36 (mental) (-0.44, p<0.001) (Table 1), and showed a good discriminatory capacity
across the different levels of disease activity (p<0.001) (Table 2).
Conclusions: The findings of this study showed that the Portuguese version of the ASAS –HI is a
comprehensible questionnaire that is reliable and valid. Therefore, its use can be recommended, both for
clinical practice and research purposes, to assess the state of health and functioning in Portuguese SpA
patients. Future research is needed to evaluate the responsiveness of the ASAS-HI in SpA patients.
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